Pharmaceuticals

FOSUN PHARMA

Fosun Pharma: Expected to submit NDA by year-end

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

Fosun Pharma Industry Acquires Exclusive Option from AriBio

Fosun Pharma Subsidiary Approved for Phase I Clinical Trial of HLX05-N for Metastatic Colorectal Cancer in the US

Fosun Pharmaceutical's Subsidiary's Venlafaxine Hydrochloride Extended-Release Tablets Approved for Registration

Fosun Pharma subsidiary obtains approval for Sodium Nitroprusside Injection registration

Fosun High-Tech Reports 9.1% Q1 Revenue Growth

Fosun Pharma Signs Strategic MOU with Arcera

Fosun Pharma Subsidiary Obtains EU Approval for Pertuzumab Injection

FOSUN PHARMA released FY2026 Q1 earnings on April 28 After-Market BJT, actual revenue HKD 11.42 B (forecast HKD 11.16 B), actual EPS HKD 0.3741 (forecast HKD 0.0226)

Fosun Pharma Reports Revenue and Net Profit Growth for Q1 2026

Morgan Stanley Raises Revenue Forecast for Fosun Pharma and Provides Stock Price Target

FOSUN PHARMA to release FY2026 Q1 earnings on April 28 After-Market (BJT), forecast revenue HKD 11.18 B, EPS HKD 0.0227

Fosun Pharma Announces 2025 Annual Report with 29.6% Growth in Innovative Drug Revenue

Fosun Pharma's Subsidiary Approved to Conduct Clinical Trials for HLX05-N in Metastatic Colorectal Cancer Treatment

Fosun Pharma's Subsidiary Wuxi Apptec Secures Market Approval for Flurbiprofen Axetil Injection

Chongqing Yoyou Pharmaceutical's Flurbiprofen Injection Obtains Drug Registration Approval

Fosun Pharma's Subsidiary's Hanlikang New Indication Approved

Fosun Pharmaceutical Publishes 2025 Annual Report

Fosun Pharma's Subsidiary Obtains Approval for HLX319 Phase I Clinical Trials for Breast Cancer

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02196

600196

520880

512010

512290

516930

Fosun Pharma and AriBio have signed an exclusive global option agreement for AR1001, a drug candidate for Alzheimer's disease. Fosun will pay AriBio a $60 million option fee and up to $180 million in milestone payments upon exercising the option. AR1001 is currently in a Phase 3 trial and has shown potential therapeutic benefits. This partnership expands their previous collaboration to global markets, aiming to accelerate the drug's development and commercialization.

PR Newswire

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

FOSUN INTL

Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease

Shanghai Fosun Pharmaceutical's subsidiary, Fosun Pharma (Xuzhou), has received approval from China's National Medical Products Administration to market Venlafaxine Hydrochloride Sustained-release Tablets, a Class 3 drug for treating depression and anxiety disorders. This approval enhances Fosun Pharma's central nervous system portfolio and competitive position in the antidepressant market. The subsidiary will act as both the marketing authorization holder and manufacturer, supporting revenue diversification. Analysts rate the stock (HK:2196) as a Buy with a target price of HK$35.30.

Tip Ranks

Fosun Pharma Subsidiary Wins China Approval for Venlafaxine SR Tablets

00656

Fosun International's subsidiaries reported solid Q1 2026 results, indicating a recovery in earnings post-risk clearance. Fosun Pharma's revenue rose 6.93% to RMB10.073 billion, with a net profit increase of 13.87%. Yuyuan's revenue grew nearly 10%, and net profit surged 203%. The company emphasizes its focus on innovative drugs, with multiple approvals and a strong pipeline. Overall, the results reflect a positive growth trajectory, reinforcing Fosun's RMB10 billion profit target for the year.

Asian Corporate Newswire

YYTM

Shede Spirits

Hainan Mining

HENLIUS

Eisai Co., Ltd.

Fosun Subsidiaries Post Solid Q1, Core Businesses Fuel Growth

Shanghai Fosun Pharmaceutical's subsidiary, Yaopharma Co., Ltd., has received approval from the National Medical Products Administration for Sodium Nitroprusside Injection, aimed at treating hypertensive emergencies and acute heart failure. This approval enhances Fosun Pharma's cardiovascular treatment portfolio and strengthens its position in critical-care therapeutics, supporting competitiveness in China's emergency cardiovascular drug market. Analysts rate the stock (HK:2196) as a Buy with a price target of HK$35.30.

Fosun Pharma Subsidiary Wins Approval for Sodium Nitroprusside Injection

CLSA reported that FOSUN PHARMAslightly missed market expectations for 1Q26, despite solid growth in revenue and profit driven by the innovative drug segment. The healthcare services segment faced pressure. Management is confident in achieving a 20% growth target for full-year 2026. CLSA maintains an Outperform rating with a target price of HKD25.4.

AASTOCKS News

CLSA: FOSUN PHARMA  1Q26 Results Slightly Miss Market Expectations

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report | FOSUF Stock News

StockTitan

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report | FOSUF Stock News

FOSUN PHARMA(02196.HK)

Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease

Fosun Pharma Subsidiary Wins China Approval for Venlafaxine SR Tablets

Fosun Subsidiaries Post Solid Q1, Core Businesses Fuel Growth

Fosun Pharma Subsidiary Wins Approval for Sodium Nitroprusside Injection

CLSA: FOSUN PHARMA 1Q26 Results Slightly Miss Market Expectations

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report | FOSUF Stock News